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Abstract 
In recent times Enterobacteriaceae including Escherichia coli and Klebsiella spp., isolated in Kumasi at the 
Komfo Anokye Teaching Hospital (KATH) have shown significant resistance to 2nd and 3rd generation 
cephalosporins. Microbial resistance to these antimicrobials if due to the production of Extended Spectrum-Beta-
Lactamases (ESBLs) may also indicate resistance to the aminoglycosides and other antibiotics. A total of 300 
non-selected, non-duplicate isolates were collected and ESBL production was phenotypically determined using 
the Combined Disc Method. 149 (49.67%) of the isolates were ESBL- producing E. coli (44.37%) or Klebsiella 
spp. (55.03%). ESBL-producing organisms were more common among in-patients (54.60%) than they were 
among out-patients (46.27%). Meropenem emerged as the antimicrobial agent of choice for the treatment of 
serious infections associated with ESBL-producers on the basis of in vitro testing. The high level of ESBL 
production found in these Enterobacteriaceae with the resultant microbial resistance to the available 
cephalosporins and other agents may pose difficulties with the choice of therapeutic options for the treatment of 
severe infections. Efforts to prevent and/or control outbreaks of infections with ESBL-producing organisms must 
emphasize on the judicious use of all antibiotics.  
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1. Introduction 
Extended-Spectrum-Beta-Lactamases (ESBLs) are enzymes which confer antibiotic resistance on certain 
bacteria in the family Enterobacteriaceae1.   
Microorganisms which produce ESBLs could be of great health concern in Kumasi at the Komfo Anokye 
Teaching Hospital (KATH) not just because they have been reported worldwide but also because in 2006, 
25.02% of all Enterobacteriaceae isolated from urine and blood, from KATH, were resistant to cephalosporins 
(cefuroxime, ceftriaxone, cefotaxime and ceftazidime) (KATH Lab records, 2006). Again, records from the 
KATH Microbiology Laboratory in 2006 indicated that, of the total Enterobacteriaceae isolated from urine and 
blood 31.19% were resistant to gentamicin (an aminoglycoside), 23.00% to ciprofloxacin (a fluoroquinolone) 
and 75.34% to tetracycline. Some of these multi-resistant isolates could probably harbour ESBLs thus limiting 
therapeutic options. The delay in detecting and reporting ESBL-producers may lead to prolonged hospitalization 
of patients, increased morbidity and mortality as well as increased cost of health care2. 
The study investigated ESBL production among E. coli and Klebsiella spp. isolated from mainly blood and urine, 
at the Komfo Anokye Teaching Hospital, Kumasi. 
 
2. Materials and Methods 
2.1 Materials 
Blood and urine samples were collected and cultures performed to isolate E. coli and Klebsiella spp. used in this 
work.  
2.2 Study Site 
This study was undertaken in Kumasi at the Microbiology laboratory of the Komfo Anokye Teaching Hospital 
(KATH).  
2.3 Sample Size 
300 non duplicate E. coli and Klebsiella spp. used in the study were isolated mainly from blood and urine in this 
study. 
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2.4 Methods 
2.4.1 Sample Collection and Culture  
The blood specimens collected were inoculated into a 25 ml brain-heart infusion broth. The bottles were then 
incubated overnight and subsequently subcultured on blood and MacConkey agar plates to isolate the 
microorganisms. The urine isolates were obtained after inoculating 20ml of mid-stream-urine onto Cysteine 
Lactose Electrolytes Deficient (CLED) agar.  
2.4.2 Data Collection 
The age, gender and location (i.e. in- or out-patient) of patients from whom the microorganisms were isolated 
were recorded.  
2.4.3 Identification of Isolates 
The isolates were identified using the API 20E (bioMérieux, France).  
2.4.4 Antimicrobial Susceptibility Testing 
Antimicrobial susceptibility of each isolate was determined by the Kirby-Bauer disc diffusion method, and 
interpreted using the British Society of Antimicrobial Chemotherapy (BSAC) standards4.  
The antibiotic discs used in this study were cefotaxime (CTX:30µg), ceftazidime (CAZ:30µg), ceftriaxone 
(CTR:30µg), cefuroxime (CXM:30µg), ampicillin (AMP:10µg), amikacin (AMK:30µg), gentamicin 
(GEN:10µg), nitrofurantoin (NIT:300µg), nalidixic acid (NAL:30µg), norfloxacin (NOR:10µg), ciprofloxacin 
(CIP:5µg), cotrimoxazole (COT:1.25/23.75µg), tetracycline (TET:30µg), chloramphenicol (CHL:30µg), 
pipemidic acid (PPA:20µg), meropenem (MEM:10µg), imipenem (IMP:10µg) and levofloxacin (LVX:5µg ). 
2.4.5 Determination of ESBL-producers 
All isolates were tested for ESBL production by the Combined Disc Method (CDM) using Cefotaxime (30 µg) 
and ceftazidime discs (30µg) or cefpodoxime (30µg) disc with and without clavulanate (10 µg) on Mueller-
Hinton agar plate.5,6 The CDM was selected for the phenotypic detection of ESBL-producers because it has a 
good sensitivity and specificity (i.e. 94.4% and 97.0% respectively) for the detection ESBL producing E. coli 
and Klebsiella spp.6 
2.4.6 Statistical Analysis 
SPSS 14 Evolution (SPSS Inc.) software was used to analyse the epidemiological data and risk factors for the 
isolation of an ESBL-producer. 
 
3. Results 
149 out of the 300 isolates studied were ESBL producers. Of the ESBL-producers, 115 were from urine (n=72) 
and blood (n=43). 37 of the ESBL-producers from urine were Klebsiella spp., and 35 E.coli. Of the 43 ESBL-
producers isolated from blood, 23 and 20 were Klebsiella spp. and E. coli respectively.  
 
Figure 1: ESBL-producers from in-patients and out-patients 
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ESBL-producers were more common among in-patients (54.60%) than out-patients (46.27%), although the 
difference was not statistically significant (OR = 1.40, 95% CI = 0.79-2.46, p= 0.30). 95 out of the 174 
organisms isolated from in-patients were ESBL-producers whilst 31out of 67 from out-patients were ESBL-
producers. (Figure 1) 
 
Table 1: Antimicrobial susceptibility profile of all isolates, non ESBL-producers and ESBL-producers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was a very high antimicrobial resistance to ampicillin, tetracycline, cotrimoxazole and chloramphenicol in 
both non ESBL-producers and ESBL-producers but a marked increase in the prevalence of drug resistance 
amongst ESBL-producers to the cephalosporins, fluoroquinolones and aminoglycosides. (Table 1) 
 
Antimicrobial 
agents 
% resistant to antimicrobial agents 
Total 
number 
Non ESBL-
producers ESBL-producers 
CTX 11.36 72.72 154 
CAZ 40.00 71.43 12 
CTR 11.96 70.58 160 
CXM 28.35 92.42 259 
AMP 93.18 96.92 262 
AMK 10.00 20.00 30 
GEN 31.94 81.43 284 
NIT 28.86 19.70 118 
NAL 60.38 80.88 121 
NOR 44.68 79.41 115 
CIP 32.35 56.73 206 
COT 80.15 96.30 271 
TET 86.27 94.23 103 
CHL 75.00 90.00 154 
PPA 50.00 73.68 31 
MEM 0.00 2.12 82 
LVX 0.00 66.67 9 
IMP 0.00 0.00 1 
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Table 2: Predictors of ESBL production 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From logistic regression analysis, resistance to any of the following antimicrobial agents, namely cefotaxime 
(OR=20.80), ceftriaxone (OR=17.67), cefuroxime (OR=30.84), gentamicin (OR=9.34), nalidixic acid (OR=2.27), 
norfloxacin (OR=4.78), ciprofloxacin (OR=2.74), cotrimoxazole (OR=6.44) and Chloramphenicol (OR=3) is 
closely associated with the production of ESBL. (Table 2) 
 
4. Discussion 
Several studies have shown that ESBL- production amongst Enterobacteriaceae is a worldwide problem7 and its 
prevalence varies from country to country. The prevalence levels of ESBL-producers obtained in this study 
(44.37% E. coli, 55.03% Klebsiella spp.) are higher than those reported for E. coli and K. pneumoniae in most 
parts of the world including, USA8, India9, China10 and Nigeria11. The high prevalence of ESBL producing K. 
pneumoniae at KATH was however comparable to the situation in Turkey which was 57.1%12.  
More than 50% of the isolates from blood (58.11%) and urine (57.14%) were ESBL-producers with blood 
accounting for the highest incidence of ESBL-producers. This observation is disturbing because of the serious 
nature of blood stream infections. Patients who were treated with any of the cephalosporins may not have 
benefited from its use as a result of treatment failures which may have been avoided if ESBL testing had been 
done.  
In contrast to findings in an earlier report13, hospitalization was not a risk factor associated with infection caused 
by ESBL-producers in this study (OR = 1.40, 95% CI = 0.79-2.46, p= 0.30). This is because ESBL producing E. 
coli or Klebsiella spp. were wide spread among both in-patients and out-patients. This observation therefore 
confirms that ESBL-producers are indeed as much a problem in the communities as in the hospitals14.  
ESBL-producers may have spread through colonized hospital equipment such as thermometers or bronchoscopes, 
and contaminated hands of health-care-givers as was reported elsewhere15. 
Most patients with ESBL- producing Klebsiella pneumoniae have their gastrointestinal tracts colonized3,15 and so 
ESBL-producers may have spread through communities, especially those with poor hygienic and sanitation 
conditions, through faecal contamination of soil and water.  
Cockroaches, which were reported to be vectors of ESBL-producers16, are common insects in many homes in 
Ghana. They could have also contributed to the spread of ESBL-producers in the community by contaminating 
Antimicrobial 
agents 
Odds 
ratio p Value 
Total number 
(n) 
CTX 20.8 0.001 154 
CAZ 3.75 0.636 12 
CTR 17.67 0.001 160 
CRX 30.84 0.001 259 
AMP 2.3 0.268 262 
AMK 2.25 0.865 30 
GEN 9.34 0.001 284 
NIT 0.61 0.348 118 
NAL 2.78 0.023 121 
NOR 4.78 0.001 115 
CIP 2.74 0.001 206 
COT 6.44 0.001 271 
TET 2.6 0.305 103 
CHL 3 0.029 154 
PPA 2.8 0.346 31 
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water and food.  
In vitro susceptibility studies of ESBL- producers showed that meropenem was the most effective against these 
isolates. However carbapenems are not easily accessible because they are too expensive for the average 
Ghanaian to purchase and they are also not covered by the National Health Insurance Scheme in Ghana.  
The carbapenems should be reserved and used to treat only serious or life threatening infections in order to 
minimize cases of carbapenem resistance though rare15. Worryingly, one ESBL producing Klebsiella pneumoniae 
was resistant to meropenem. This is of great concern given that Klebsiellae have a high propensity to host 
plasmids15. Appropriate prevention and infection control measures must be put in place to prevent the spread of 
these strains within the hospital and the community.  
Amikacin was also very effective against ESBL-producers isolated from blood and urine. 
Interestingly ciprofloxacin was very effect against isolates from blood but not effective against those from urine. 
ESBL-producers isolated from urine were generally susceptible to Nitrofurantoin.  
It has been reported that the increasing use of ciprofloxacin in the community in many countries has resulted in 
quinolone resistance in Enterobacteriaceae17. In Ghana ciprofloxacin is recommended for the treatment of many 
infections including urinary tract infections, typhoid fever, acute gonorrhoea and osteomylitis18. Unfortunately 
many individuals abuse ciprofloxacin, when they have recurrent malaria, on the assumption that they have 
typhoid fever. 
Routine antimicrobial suseptibility testing may not identify ESBL-producing organisms and so, if the ESBL test 
had been performed, all  the ESBL- producing strains would have been reported as resistant to all penicillins, 
cephalosporins and aztreonam as recommended by CLSI.5 The false sensitives (23.21%) recorded especially for 
the cephalosporins  which may have resulted in treatment failure and prolonged hospital stay may have been 
avoided. 
The high odds ratio for ESBL-producers being reported as resistant to cefotaxime (OR=20.80), ceftriaxone 
(OR=17.67), cefuroxime (OR=30.84), gentamicin (OR=9.34), nalidixic acid (OR=2.27), norfloxacin (OR=4.78), 
ciprofloxacin (OR=2.74) and cotrimoxazole (OR=6.44) show that there is a close association between the high 
levels of resistance observed in Kumasi at KATH and the production of ESBL by E. coli and Klebsiella spp. It 
also confirms reports that ESBL production confers resistance to several of the commonly used antimicrobials 
such as gentamicin10, cotrimoxazole, and fluoroquinolones.9,15 Chloramphenicol, a phenicol, was also co-
resistant with cephalosporins in the presence of an ESBL producing E. coli or Klebsiella spp. (OR= 3.00, 95% CI 
1.19-7.56,   p = 0.029). 
 Any E. coli or Klebsiella spp.  isolated in Kumasi at KATH which is resistant to cefotaxime, ceftriaxone, 
cefuroxime, gentamicin, nalidixic acid, norfloxacin, ciprofloxacin, cotrimoxazole and chloramphenicol should be 
regarded as a potential ESBL-producer, and hence it should undergo ESBL testing. This is because there was a 
close association between ESBL production and resistance to any of the above mentioned antimicrobial agents 
by these organisms.  
 
5. Conclusion 
This study has shown that there is a high prevalence of ESBL producing E. coli and Klebsiella spp. Kumasi. This 
was partly responsible for the high levels of resistance of E. coli and Klebsiella spp. to the fluoroquinolones and 
cephalosporins. ESBL-producers were generally resistant to the quinolones, aminoglycosides, tetracyclines, 
trimethoprim-sulfamethoxazole and phenicol but susceptible to the carbapenems. There was however no 
independent risk factor associated with the isolation of an ESBL producing E. coli or Klebsiella spp. in this study 
in terms of  age, gender and location (i.e. In-/ Out-patient)  of a patient. 
Based on this study ESBL detection should be performed routinely on all isolates of E. coli and Klebsiella spp. 
Amikacin and Ciprofloxacin should be recommended for treatment whenever ESBL-producers are susceptible to 
them and Nitrofurantoin should also be considered as the drug of choice whenever an ESBL-producer isolated 
from urine is susceptible to it. Meropenem should be considered for treatment of only serious or life threatening 
infections. 
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